Accessibility StatementSkip Navigation HAMILTON, Bermuda, Oct. 22, 2025 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore" or the "Company") today announced that the Company plans to announce its third quarter earnings before the market opens Wednesday, November 5, 2025 and will host a conference call later in the day at 10:00 a.m. Eastern Time. The conference call and slide presentation will also be broadcast live over the Internet. Conference Call and Webcast Details: If you are unable to ...

With a professional background spanning multiple industries, from logistics, construction to retail, I bring a diverse perspective to investing. My international education and career experiences have provided me with a global outlook and the ability to analyze market dynamics from different cultural and economic perspectives. I have been actively investing for over a decade, honing a strategy that focuses on cyclical industries while maintaining a diversified portfolio that includes bonds, commodities, and ...

, /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it recently completed the pre-New Drug Application (NDA) consultation with China National Medical Products Administration (NMPA) for denifanstat (ASC40) for the treatment of moderate-to-severe acne vulgaris and plans to submit an NDA soon. The pre-NDA consultation was initiated from June 2025 and completed in October 2025. - Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) ...

British online fashion retailer ASOS warned on Tuesday that annual revenue would come in below market expectations, citing subdued consumer demand and a slow recovery in its fast-fashion business. ...

Core Insights - The gastrointestinal tolerability of ASC47 in combination with semaglutide is significantly better than that of semaglutide monotherapy, indicating a potential advantage for ASC47 in clinical applications [1] Group 1 - The incidence of vomiting in the ASC47 plus semaglutide group was 6.7%, compared to 57.1% in the semaglutide monotherapy group, highlighting a substantial difference in tolerability [1]

Core Insights - Denifanstat (ASC40) has met all primary, key secondary, and secondary efficacy endpoints in treating moderate-to-severe acne compared to placebo [1][6][11] - The drug demonstrated a favorable safety and tolerability profile, with treatment-emergent adverse events (TEAEs) comparable to placebo [1][9] Efficacy Results - The Phase III clinical trial involved 480 patients, randomized into treatment and placebo groups, showing significant improvements in multiple efficacy endpoints after 4 weeks and 12 weeks of treatment [4][6] - Primary endpoints included a treatment success rate of 33.17% for denifanstat compared to 14.58% for placebo, with a p-value of <0.0001 [5][6] - Percent reductions from baseline to week 12 in total lesion count (TLC) and inflammatory lesion count (ILC) were 57.38% and 63.45% for denifanstat, respectively, both statistically significant [6][7] Safety Profile - The incidence of TEAEs was 58.6% for denifanstat and 56.3% for placebo, with most events being mild or moderate [9] - Notable TEAEs included 6.3% dry skin and 5.9% xerophthalmia in the denifanstat group, with no serious adverse events reported [9] Regulatory Progress - Ongoing pre-New Drug Application (NDA) consultation with the China National Medical Products Administration (NMPA) has yielded encouraging feedback, with plans to submit an NDA for denifanstat after consultation completion [2][11] Company Background - Ascletis Pharma Inc. is focused on developing and commercializing innovative therapeutics for metabolic diseases, utilizing advanced drug discovery platforms [13]

Core Insights - The article emphasizes the importance of efficiency ratios as indicators of a company's financial health and operational efficiency [1] Efficiency Ratios - **Receivables Turnover**: This ratio measures a company's ability to extend credit and collect debts, with a higher ratio indicating better performance [2] - **Asset Utilization**: This ratio assesses how effectively a company converts its assets into sales, with higher values suggesting greater efficiency [3] - **Inventory Turnover**: This ratio indicates a company's ability to manage inventory relative to its cost of goods sold, with higher values reflecting better inventory management [4] - **Operating Margin**: This ratio measures the efficiency of a company in controlling operating expenses relative to sales, with higher values indicating better expense management [5] Screening Process - A screening process was applied to identify stocks with efficiency ratios above industry averages, narrowing down from over 7,906 stocks to 18 [7] - The screening criteria included turnover ratios, asset utilization, and operating margin, along with a favorable Zacks Rank of 1 (Strong Buy) [6][8] Selected Companies - **Post Holdings (POST)**: A consumer-packaged goods holding company with a positive earnings surprise of 21.4% [7] - **BuildABear Workshop (BBW)**: A leading interactive retail-entertainment company with a positive earnings surprise of 21.3% [9] - **Equity Bancshares (EQBK)**: A financial services provider with a positive earnings surprise of 17.9% [10] - **Ardmore Shipping (ASC)**: Engaged in the ownership and operation of tankers, with a positive earnings surprise of 9.6% [11] - **Sally Beauty (SBH)**: An international retailer of beauty supplies with a positive earnings surprise of 8.3% [12]

Core Viewpoint - Pambili Natural Resources Corporation has secured C$138,500 as the first tranche of a C$1-million non-brokered private placement, aimed at supporting its operations and financial reporting requirements [1][4]. Funding Details - The first tranche consists of 2,770,000 Units, each priced at C$0.05, which includes one common share and one warrant with an exercise price of C$0.10, valid for one year [2][3]. - The total proceeds from the tranche will be allocated to various expenses, including C$90,000 for audit fees, C$15,000 for accounting fees, C$15,000 for legal fees, C$8,500 for filing fees, and C$10,000 for general and administrative costs [4]. Regulatory Context - The company is currently under a Failure to File Cease Trade Order (FFCTO) issued by the Alberta Securities Commission, and it has applied for a partial revocation to facilitate the closing of the tranche [2][4]. - The completion of the offering is contingent upon the approval from the Alberta Securities Commission and the TSX Venture Exchange [2][4]. Management Commentary - The CEO of Pambili expressed optimism regarding the company's gold projects in Zimbabwe, highlighting the potential for growth in the current high gold price environment [5].

Core Viewpoint - The Zacks Transportation - Shipping industry is facing challenges such as inflation, high interest rates, tariffs, and supply chain disruptions, but there are positive factors like a 90-day extension on tariffs against China, low oil prices, and improved demand for goods and commodities post-pandemic [1][4]. Industry Overview - The Zacks Transportation - Shipping industry is cyclical and primarily provides liquefied natural gas and crude oil marine transportation services under long-term contracts with major energy and utility companies. The industry is heavily reliant on the health of the economy, with a recovery from COVID-19 standstill benefiting its prospects [3]. Shipping Industry Trends - The extension of the tariff deadline on Chinese goods is a significant positive for the shipping industry, likely leading to a short-term increase in imports and stabilizing global trade flows [4]. - Elevated compliance costs due to regulations and rising technology-related expenses are expected to impact profits in the short term, but these investments will support long-term margins [5]. - The demand for liquefied natural gas (LNG) is increasing, particularly due to geopolitical factors, which is favorable for shipping stocks [6]. - Low oil prices are beneficial for the industry as they reduce fuel costs, which are a major expense for transportation companies. Oil prices have declined by 6% in the April-June period, benefiting oil tanker companies [7]. Industry Performance - The Zacks Transportation - Shipping industry has underperformed compared to the S&P 500 index, declining by 20.2% over the past year, while the S&P 500 increased by 16% [11]. - The industry currently has a Zacks Industry Rank of 98, placing it in the top 40% of 246 Zacks industries, indicating positive near-term prospects [9]. Valuation - The industry is trading at a forward price-to-earnings (P/E) ratio of 6.82X, significantly lower than the S&P 500's 22.86X and the sector's 14.36X [14]. Stock Recommendations - Dorian LPG has seen a stock increase of 56% over the past six months, driven by rising demand for liquefied petroleum gases [16]. - Euroseas has gained 41% over the past year, benefiting from profitable contracts and a time charter equivalent rate exceeding $30,000 per day [20]. - Ardmore Shipping's stock has increased by 18% over the past six months, with a focus on product and chemical tankers [23].

Group 1: Ardmore Shipping (ASC) - Ardmore Shipping is engaged in the ownership and operation of product and chemical tankers, carrying a Zacks Rank 1 (Strong Buy) [1] - The Zacks Consensus Estimate for Ardmore Shipping's current year earnings has increased by 2.6% over the last 60 days [1] - The company has a price-to-earnings ratio (P/E) of 9.15, significantly lower than the industry average of 19.5, and possesses a Value Score of A [2] Group 2: Dillard's (DDS) - Dillard's is a large departmental store chain featuring fashion apparel and home furnishings, also carrying a Zacks Rank 1 [2] - The Zacks Consensus Estimate for Dillard's current year earnings has increased by 2.6% over the last 60 days [2] - Dillard's has a price-to-earnings ratio (P/E) of 16.25, which is lower than the industry average of 19.80, and possesses a Value Score of A [3] Group 3: Healthcare Services Group (HCSG) - Healthcare Services Group provides housekeeping, laundry, linen, facility maintenance, and food services to the healthcare industry, including nursing homes and hospitals, and carries a Zacks Rank 1 [4] - The Zacks Consensus Estimate for Healthcare Services Group's current year earnings has increased by 4.8% over the last 60 days [4] - The company has a price-to-earnings ratio (P/E) of 17.31, compared to the industry average of 21.10, and possesses a Value Score of A [5]